Eisenmenger syndrome is a rare and complex heart condition that develops as a result of certain congenital heart defects. It is named after a Swiss physician named Victor Eisenmenger, who first described the syndrome in 1897. Eisenmenger syndrome is characterized by the reversal or shunting of blood flow within the heart due to a specific heart defect.
In individuals with these defects, the abnormal connection causes blood to flow from the higher-pressure systemic circulation into the lower-pressure pulmonary circulation. Over time, this increased blood flow causes the blood vessels in the lungs to become thickened and narrowed, a condition known as pulmonary hypertension. Eisenmenger syndrome is a progressive condition and can vary in severity among affected individuals.
Epidemiology
The epidemiology of Eisenmenger syndrome is relatively rare, as it is a consequence of specific congenital heart defects rather than a standalone condition. The prevalence of congenital heart defects, including those associated with Eisenmenger syndrome, is estimated to be around 8 per 1,000 live births.
Among individuals with congenital heart defects, approximately 6-10% may develop Eisenmenger syndrome. The incidence of Eisenmenger syndrome varies based on the specific underlying heart defect. For instance, among patients with ventricular septal defect (VSD) or atrial septal defect (ASD), the risk of developing Eisenmenger syndrome is estimated to be around 5-10%.
The incidence of patent ductus arteriosus (PDA) is lower, ranging from 0.7% to 2.7%. Eisenmenger syndrome tends to be more common in females than males, with a female-to-male ratio of approximately 1.5:1. The reason for this gender difference is not well understood.
Anatomy
Pathophysiology
The pathophysiology of Eisenmenger syndrome is closely tied to the underlying congenital heart defects and the subsequent development of pulmonary hypertension. Eisenmenger syndrome arises from certain congenital heart defects, including ventricular septal defect, atrial septal defect, and patent ductus arteriosus. These defects result in abnormal connections or openings between the chambers of the heart or major blood vessels.
These defects allow blood to flow from the higher-pressure left side of the heart (systemic circulation) to the lower-pressure right side of the heart (pulmonary circulation). This results in a left-to-right shunt, where oxygenated blood mixes with deoxygenated blood, but there is an excessive blood flow to the lungs. Over time, the increased blood flow to the lungs causes the small blood vessels to become thickened, narrowed, and resistant to blood flow. The narrowing of the pulmonary vessels raises the pressure within the pulmonary circulation.
As pulmonary hypertension progresses, the pressure within the pulmonary arteries eventually exceeds that of the systemic arteries. This reversal of the shunt causes deoxygenated blood from the right side of the heart to flow back into the left side of the heart and mix with oxygenated blood. This leads to systemic desaturation, meaning the oxygen levels in the systemic circulation are lower than normal. The mixing of oxygenated and deoxygenated blood results in reduced oxygen levels in the systemic circulation.
Etiology
The etiology of Eisenmenger syndrome lies in the presence of specific congenital heart defects, primarily ventricular septal defect (VSD), atrial septal defect (ASD), and patent ductus arteriosus (PDA). These defects create abnormal connections or openings between the heart chambers or major blood vessels.
The exact cause of these congenital heart defects is not always known, but they are thought to result from genetic and environmental factors. Genetic mutations, chromosomal abnormalities, and maternal exposure to certain medications or infections during pregnancy can contribute to the development of these defects.
It’s important to note that while these defects are present from birth, the progression to Eisenmenger syndrome is not inevitable and can be influenced by factors such as the size and location of the defect, pulmonary vascular resistance, and individual variations in response to increased blood flow.
Genetics
Prognostic Factors
Individuals diagnosed with Eisenmenger syndrome typically experience a decrease in life expectancy, particularly with higher mortality rates during their thirties and forties. Common causes of death in these patients include ventricular failure, hemoptysis, complications during pregnancy, and strokes.
Clinical History
Clinical History
The patient’s clinical history often starts with the diagnosis of a congenital heart defect such as ventricular septal defect (VSD), atrial septal defect (ASD), or patent ductus arteriosus (PDA) during infancy or childhood. This initial diagnosis may be based on symptoms, physical examination findings, and diagnostic tests such as echocardiography.
As the patient grows older, symptoms associated with Eisenmenger syndrome may develop. These can include cyanosis, shortness of breath, fatigue, dizziness, chest pain, palpitations, and clubbing of the fingers and toes.
Over time, pulmonary hypertension develops due to the increased blood flow to the lungs. This can lead to the reversal of the shunt, where deoxygenated blood from the right side of the heart flows back into the left side. This results in systemic desaturation and further exacerbates the cyanosis and symptoms.
Physical Examination
Physical Examination
Several specific findings may be observed during a physical examination of a patient with Eisenmenger syndrome. These findings can provide important clues to the underlying condition and its severity. One of the hallmark signs of Eisenmenger syndrome is cyanosis, a bluish discoloration of the skin, lips, and mucous membranes.
It is caused by mixing oxygenated and deoxygenated blood in the systemic circulation. Clubbing of the fingers and toes may be present. This refers to the enlargement and rounding of the fingertips and the nails becoming abnormally curved. It results from chronic low oxygen levels and changes in the peripheral blood vessels.
The P2 sound is accentuated due to increased pressure in the pulmonary arteries. A systolic murmur may be heard, caused by increased blood flow across the abnormal connection or defect, such as a VSD or ASD. As a consequence of increased pressure in the pulmonary circulation, the right ventricle of the heart may undergo hypertrophy (thickening of the muscle). This can be detected by palpation and percussion of the chest and certain electrocardiogram findings.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Differential Diagnoses
Hepatitis B
Hepatitis C
Mixed Connective Tissue Disorder
Scleroderma
Systemic Lupus Erythematosus
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Pharmacological options for the management of Eisenmenger syndrome encompass several categories, including antiarrhythmics, diuretics and anticoagulants in select cases. Vasodilator therapies have shown promise and are subjects of ongoing clinical research, with some studies demonstrating symptomatic improvement.
The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) trial demonstrated enhanced exercise capacity and symptomatic relief in patients with Eisenmenger syndrome associated with atrial septal defect, ventricular septal defect, and patent ductus arteriosus when treated with endothelin antagonists.
Warfarin has traditionally been used for anticoagulation in Eisenmenger syndrome to mitigate the risk of in situ thrombosis; however, the evidence supporting this practice largely stems from observational studies. Surgical correction of the underlying heart defect is generally contraindicated in adults.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
News
Rare Uterine Lipoma Diagnosed Post-Surgery: Case Report
Posted on
News
Robotic Breakthrough in Brain Surgery
Posted on
News
Bangladesh Achieves Remarkable Reduction in Lead in Turmeric
Posted on
News
Suppressing Negative Thoughts Can Improve Mental Health
Eisenmenger syndrome is a rare and complex heart condition that develops as a result of certain congenital heart defects. It is named after a Swiss physician named Victor Eisenmenger, who first described the syndrome in 1897. Eisenmenger syndrome is characterized by the reversal or shunting of blood flow within the heart due to a specific heart defect.
In individuals with these defects, the abnormal connection causes blood to flow from the higher-pressure systemic circulation into the lower-pressure pulmonary circulation. Over time, this increased blood flow causes the blood vessels in the lungs to become thickened and narrowed, a condition known as pulmonary hypertension. Eisenmenger syndrome is a progressive condition and can vary in severity among affected individuals.
The epidemiology of Eisenmenger syndrome is relatively rare, as it is a consequence of specific congenital heart defects rather than a standalone condition. The prevalence of congenital heart defects, including those associated with Eisenmenger syndrome, is estimated to be around 8 per 1,000 live births.
Among individuals with congenital heart defects, approximately 6-10% may develop Eisenmenger syndrome. The incidence of Eisenmenger syndrome varies based on the specific underlying heart defect. For instance, among patients with ventricular septal defect (VSD) or atrial septal defect (ASD), the risk of developing Eisenmenger syndrome is estimated to be around 5-10%.
The incidence of patent ductus arteriosus (PDA) is lower, ranging from 0.7% to 2.7%. Eisenmenger syndrome tends to be more common in females than males, with a female-to-male ratio of approximately 1.5:1. The reason for this gender difference is not well understood.
The pathophysiology of Eisenmenger syndrome is closely tied to the underlying congenital heart defects and the subsequent development of pulmonary hypertension. Eisenmenger syndrome arises from certain congenital heart defects, including ventricular septal defect, atrial septal defect, and patent ductus arteriosus. These defects result in abnormal connections or openings between the chambers of the heart or major blood vessels.
These defects allow blood to flow from the higher-pressure left side of the heart (systemic circulation) to the lower-pressure right side of the heart (pulmonary circulation). This results in a left-to-right shunt, where oxygenated blood mixes with deoxygenated blood, but there is an excessive blood flow to the lungs. Over time, the increased blood flow to the lungs causes the small blood vessels to become thickened, narrowed, and resistant to blood flow. The narrowing of the pulmonary vessels raises the pressure within the pulmonary circulation.
As pulmonary hypertension progresses, the pressure within the pulmonary arteries eventually exceeds that of the systemic arteries. This reversal of the shunt causes deoxygenated blood from the right side of the heart to flow back into the left side of the heart and mix with oxygenated blood. This leads to systemic desaturation, meaning the oxygen levels in the systemic circulation are lower than normal. The mixing of oxygenated and deoxygenated blood results in reduced oxygen levels in the systemic circulation.
The etiology of Eisenmenger syndrome lies in the presence of specific congenital heart defects, primarily ventricular septal defect (VSD), atrial septal defect (ASD), and patent ductus arteriosus (PDA). These defects create abnormal connections or openings between the heart chambers or major blood vessels.
The exact cause of these congenital heart defects is not always known, but they are thought to result from genetic and environmental factors. Genetic mutations, chromosomal abnormalities, and maternal exposure to certain medications or infections during pregnancy can contribute to the development of these defects.
It’s important to note that while these defects are present from birth, the progression to Eisenmenger syndrome is not inevitable and can be influenced by factors such as the size and location of the defect, pulmonary vascular resistance, and individual variations in response to increased blood flow.
Individuals diagnosed with Eisenmenger syndrome typically experience a decrease in life expectancy, particularly with higher mortality rates during their thirties and forties. Common causes of death in these patients include ventricular failure, hemoptysis, complications during pregnancy, and strokes.
Clinical History
The patient’s clinical history often starts with the diagnosis of a congenital heart defect such as ventricular septal defect (VSD), atrial septal defect (ASD), or patent ductus arteriosus (PDA) during infancy or childhood. This initial diagnosis may be based on symptoms, physical examination findings, and diagnostic tests such as echocardiography.
As the patient grows older, symptoms associated with Eisenmenger syndrome may develop. These can include cyanosis, shortness of breath, fatigue, dizziness, chest pain, palpitations, and clubbing of the fingers and toes.
Over time, pulmonary hypertension develops due to the increased blood flow to the lungs. This can lead to the reversal of the shunt, where deoxygenated blood from the right side of the heart flows back into the left side. This results in systemic desaturation and further exacerbates the cyanosis and symptoms.
Physical Examination
Several specific findings may be observed during a physical examination of a patient with Eisenmenger syndrome. These findings can provide important clues to the underlying condition and its severity. One of the hallmark signs of Eisenmenger syndrome is cyanosis, a bluish discoloration of the skin, lips, and mucous membranes.
It is caused by mixing oxygenated and deoxygenated blood in the systemic circulation. Clubbing of the fingers and toes may be present. This refers to the enlargement and rounding of the fingertips and the nails becoming abnormally curved. It results from chronic low oxygen levels and changes in the peripheral blood vessels.
The P2 sound is accentuated due to increased pressure in the pulmonary arteries. A systolic murmur may be heard, caused by increased blood flow across the abnormal connection or defect, such as a VSD or ASD. As a consequence of increased pressure in the pulmonary circulation, the right ventricle of the heart may undergo hypertrophy (thickening of the muscle). This can be detected by palpation and percussion of the chest and certain electrocardiogram findings.
Differential Diagnoses
Hepatitis B
Hepatitis C
Mixed Connective Tissue Disorder
Scleroderma
Systemic Lupus Erythematosus
Pharmacological options for the management of Eisenmenger syndrome encompass several categories, including antiarrhythmics, diuretics and anticoagulants in select cases. Vasodilator therapies have shown promise and are subjects of ongoing clinical research, with some studies demonstrating symptomatic improvement.
The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) trial demonstrated enhanced exercise capacity and symptomatic relief in patients with Eisenmenger syndrome associated with atrial septal defect, ventricular septal defect, and patent ductus arteriosus when treated with endothelin antagonists.
Warfarin has traditionally been used for anticoagulation in Eisenmenger syndrome to mitigate the risk of in situ thrombosis; however, the evidence supporting this practice largely stems from observational studies. Surgical correction of the underlying heart defect is generally contraindicated in adults.
medtigo
Eissenmenger syndrome
Updated :
August 24, 2023
Eisenmenger syndrome is a rare and complex heart condition that develops as a result of certain congenital heart defects. It is named after a Swiss physician named Victor Eisenmenger, who first described the syndrome in 1897. Eisenmenger syndrome is characterized by the reversal or shunting of blood flow within the heart due to a specific heart defect.
In individuals with these defects, the abnormal connection causes blood to flow from the higher-pressure systemic circulation into the lower-pressure pulmonary circulation. Over time, this increased blood flow causes the blood vessels in the lungs to become thickened and narrowed, a condition known as pulmonary hypertension. Eisenmenger syndrome is a progressive condition and can vary in severity among affected individuals.
The epidemiology of Eisenmenger syndrome is relatively rare, as it is a consequence of specific congenital heart defects rather than a standalone condition. The prevalence of congenital heart defects, including those associated with Eisenmenger syndrome, is estimated to be around 8 per 1,000 live births.
Among individuals with congenital heart defects, approximately 6-10% may develop Eisenmenger syndrome. The incidence of Eisenmenger syndrome varies based on the specific underlying heart defect. For instance, among patients with ventricular septal defect (VSD) or atrial septal defect (ASD), the risk of developing Eisenmenger syndrome is estimated to be around 5-10%.
The incidence of patent ductus arteriosus (PDA) is lower, ranging from 0.7% to 2.7%. Eisenmenger syndrome tends to be more common in females than males, with a female-to-male ratio of approximately 1.5:1. The reason for this gender difference is not well understood.
The pathophysiology of Eisenmenger syndrome is closely tied to the underlying congenital heart defects and the subsequent development of pulmonary hypertension. Eisenmenger syndrome arises from certain congenital heart defects, including ventricular septal defect, atrial septal defect, and patent ductus arteriosus. These defects result in abnormal connections or openings between the chambers of the heart or major blood vessels.
These defects allow blood to flow from the higher-pressure left side of the heart (systemic circulation) to the lower-pressure right side of the heart (pulmonary circulation). This results in a left-to-right shunt, where oxygenated blood mixes with deoxygenated blood, but there is an excessive blood flow to the lungs. Over time, the increased blood flow to the lungs causes the small blood vessels to become thickened, narrowed, and resistant to blood flow. The narrowing of the pulmonary vessels raises the pressure within the pulmonary circulation.
As pulmonary hypertension progresses, the pressure within the pulmonary arteries eventually exceeds that of the systemic arteries. This reversal of the shunt causes deoxygenated blood from the right side of the heart to flow back into the left side of the heart and mix with oxygenated blood. This leads to systemic desaturation, meaning the oxygen levels in the systemic circulation are lower than normal. The mixing of oxygenated and deoxygenated blood results in reduced oxygen levels in the systemic circulation.
The etiology of Eisenmenger syndrome lies in the presence of specific congenital heart defects, primarily ventricular septal defect (VSD), atrial septal defect (ASD), and patent ductus arteriosus (PDA). These defects create abnormal connections or openings between the heart chambers or major blood vessels.
The exact cause of these congenital heart defects is not always known, but they are thought to result from genetic and environmental factors. Genetic mutations, chromosomal abnormalities, and maternal exposure to certain medications or infections during pregnancy can contribute to the development of these defects.
It’s important to note that while these defects are present from birth, the progression to Eisenmenger syndrome is not inevitable and can be influenced by factors such as the size and location of the defect, pulmonary vascular resistance, and individual variations in response to increased blood flow.
Individuals diagnosed with Eisenmenger syndrome typically experience a decrease in life expectancy, particularly with higher mortality rates during their thirties and forties. Common causes of death in these patients include ventricular failure, hemoptysis, complications during pregnancy, and strokes.
Clinical History
The patient’s clinical history often starts with the diagnosis of a congenital heart defect such as ventricular septal defect (VSD), atrial septal defect (ASD), or patent ductus arteriosus (PDA) during infancy or childhood. This initial diagnosis may be based on symptoms, physical examination findings, and diagnostic tests such as echocardiography.
As the patient grows older, symptoms associated with Eisenmenger syndrome may develop. These can include cyanosis, shortness of breath, fatigue, dizziness, chest pain, palpitations, and clubbing of the fingers and toes.
Over time, pulmonary hypertension develops due to the increased blood flow to the lungs. This can lead to the reversal of the shunt, where deoxygenated blood from the right side of the heart flows back into the left side. This results in systemic desaturation and further exacerbates the cyanosis and symptoms.
Physical Examination
Several specific findings may be observed during a physical examination of a patient with Eisenmenger syndrome. These findings can provide important clues to the underlying condition and its severity. One of the hallmark signs of Eisenmenger syndrome is cyanosis, a bluish discoloration of the skin, lips, and mucous membranes.
It is caused by mixing oxygenated and deoxygenated blood in the systemic circulation. Clubbing of the fingers and toes may be present. This refers to the enlargement and rounding of the fingertips and the nails becoming abnormally curved. It results from chronic low oxygen levels and changes in the peripheral blood vessels.
The P2 sound is accentuated due to increased pressure in the pulmonary arteries. A systolic murmur may be heard, caused by increased blood flow across the abnormal connection or defect, such as a VSD or ASD. As a consequence of increased pressure in the pulmonary circulation, the right ventricle of the heart may undergo hypertrophy (thickening of the muscle). This can be detected by palpation and percussion of the chest and certain electrocardiogram findings.
Differential Diagnoses
Hepatitis B
Hepatitis C
Mixed Connective Tissue Disorder
Scleroderma
Systemic Lupus Erythematosus
Pharmacological options for the management of Eisenmenger syndrome encompass several categories, including antiarrhythmics, diuretics and anticoagulants in select cases. Vasodilator therapies have shown promise and are subjects of ongoing clinical research, with some studies demonstrating symptomatic improvement.
The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) trial demonstrated enhanced exercise capacity and symptomatic relief in patients with Eisenmenger syndrome associated with atrial septal defect, ventricular septal defect, and patent ductus arteriosus when treated with endothelin antagonists.
Warfarin has traditionally been used for anticoagulation in Eisenmenger syndrome to mitigate the risk of in situ thrombosis; however, the evidence supporting this practice largely stems from observational studies. Surgical correction of the underlying heart defect is generally contraindicated in adults.
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
